BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36630607)

  • 21. Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.
    Kuravi S; Cheng J; Fangman G; Polireddy K; McCormick S; Lin TL; Singh AK; Abhyankar S; Ganguly S; Welch DR; Jensen RA; McGuirk JP; Balusu R
    Mol Cancer Res; 2021 May; 19(5):913-920. PubMed ID: 33514657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
    Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
    Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JAK/STAT3 Signaling Activation Related to Distinct Clinicopathologic Features in Systemic ALK - Anaplastic Large Cell Lymphomas : New Insights into Their Heterogeneity.
    Wang JC; Zhong LH; Lin WQ; Zhang WF; Xi YF; Liu YP; Zhu Q; Liu W; Zhu WF; Chen YP; Chen G
    Am J Surg Pathol; 2023 Jan; 47(1):55-64. PubMed ID: 36315833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.
    Hoareau-Aveilla C; Quelen C; Congras A; Caillet N; Labourdette D; Dozier C; Brousset P; Lamant L; Meggetto F
    Haematologica; 2019 Feb; 104(2):347-359. PubMed ID: 30262555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALK-Negative Anaplastic Large Cell Lymphoma (ALCL): Prognostic Implications of Molecular Subtyping and JAK-STAT Pathway.
    Parkhi M; Bal A; Das A; Kashyap D; Bhardwaj S; Prakash G; Malhotra P
    Appl Immunohistochem Mol Morphol; 2021 Oct; 29(9):648-656. PubMed ID: 33901030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
    Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
    BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma.
    Hwang SR; Murga-Zamalloa C; Brown N; Basappa J; McDonnell SR; Mendoza-Reinoso V; Basrur V; Wilcox R; Elenitoba-Johnson K; Lim MS
    Lab Invest; 2017 Aug; 97(8):962-970. PubMed ID: 28414323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.
    Zhang J; Wang P; Wu F; Li M; Sharon D; Ingham RJ; Hitt M; McMullen TP; Lai R
    Cell Signal; 2012 Apr; 24(4):852-8. PubMed ID: 22155737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Anand M; Lai R; Gelebart P
    Haematologica; 2011 Feb; 96(2):253-61. PubMed ID: 20971814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3.
    Gambi G; Di Simone E; Basso V; Ricci L; Wang R; Verma A; Elemento O; Ponzoni M; Inghirami G; Icardi L; Mondino A
    Cancer Res; 2019 Jun; 79(12):3076-3087. PubMed ID: 30692217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
    Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.
    Wang P; Zhang JD; Wu F; Ye X; Sharon D; Hitt M; McMullen TP; Hegazy SA; Gelebart P; Yang J; Ma Y; Lai R
    Cell Signal; 2012 Oct; 24(10):1955-63. PubMed ID: 22743134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.
    Martinengo C; Poggio T; Menotti M; Scalzo MS; Mastini C; Ambrogio C; Pellegrino E; Riera L; Piva R; Ribatti D; Pastorino F; Perri P; Ponzoni M; Wang Q; Voena C; Chiarle R
    Cancer Res; 2014 Nov; 74(21):6094-106. PubMed ID: 25193384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma.
    Rajan SS; Amin AD; Li L; Rolland DC; Li H; Kwon D; Kweh MF; Arumov A; Roberts ER; Yan A; Basrur V; Elenitoba-Johnson KSJ; Chen XS; Puvvada SD; Lussier YA; Bilbao D; Lim MS; Schatz JH
    Oncogene; 2020 Mar; 39(10):2103-2117. PubMed ID: 31804622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.
    Toda T; Watanabe M; Kawato J; Kadin ME; Higashihara M; Kunisada T; Umezawa K; Horie R
    Br J Haematol; 2015 Sep; 170(6):837-46. PubMed ID: 26105086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel model of controlling PD-L1 expression in ALK
    Zhang JP; Song Z; Wang HB; Lang L; Yang YZ; Xiao W; Webster DE; Wei W; Barta SK; Kadin ME; Staudt LM; Nakagawa M; Yang Y
    Blood; 2019 Jul; 134(2):171-185. PubMed ID: 31151983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.
    Kasprzycka M; Marzec M; Liu X; Zhang Q; Wasik MA
    Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9964-9. PubMed ID: 16766651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.
    Dien Bard J; Gelebart P; Anand M; Zak Z; Hegazy SA; Amin HM; Lai R
    Am J Pathol; 2009 Aug; 175(2):825-34. PubMed ID: 19608866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.